Tranzyme Pharma, which closed recently on $26 million in venture capital based on the promise of its line of drug candidates, reported more positive clinical data on its lead candidate Thursday.

In laboratory tests, Tranzyme said its TZP-101 showed promise in treatment of gastrointestinal disorders. The results were reported at a conference in Chicago. The tests were conducted on rats at the University of Oklahoma Health Sciences Center by Beverly Greenwood-Van Meerveld, a gastrointestinal researcher.

Tranzyme said it plans to pursue an investigational new drug filing with the FDA by the fourth quarter and launch Phase I clinical trials before the end of the year.